Our Scientific Advisory Committee

Thierry Dorval

Head of Data Sciences & Data Management, Servier

Thierry Dorval received a Ph.D. in image analysis and Artificial Intelligence from University Pierre & Marie Curie and then joined the institut Pasteur Korea in 2005 as a group leader specialized in High Content Screening applied to cellular differentiation and toxicity prediction.

In 2012 he joined AstraZeneca, where his activities were about developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screening.

In 2015 he joined Institut de Recherches Servier, France, to lead the Data Sciences & Data Management pole of activities where he is in charge of optimizing the early stages of the drug discovery by taking advantage of cutting-edge computational approaches. This includes usage of Artificial Intelligence, knowledge graph database and RNA sequences design.

Christine Klein

Director, Institute of Neurogenetics, University of Lübeck

Christine Klein is a Professor of Neurology and Neurogenetics. She carried out fellowships with Prof. Breakefield (Boston) and Prof. Lang (Toronto). She was appointed Lichtenberg Professor at Luebeck University in 2005 and Schilling Professor of Clinical and Molecular Neurogenetics in 2009. She became Director of the newly founded Institute of Neurogenetics in 2013, and a member of the National Academy of Sciences Leopoldina in 2021. She is the current Chair of the European Section of the MDS (MDS-ES) and lead of the Monogenic Network of the Global Parkinson’s Genetics Program (https://gp2.org).

Alleyn Plowright, pHD

CSO and Drug Discovery Leader, Pangea Bio

Dr Alleyn Plowright is Chief Scientific Officer at PangeaBio. He is a proven drug discovery leader with >20 years experience across a range of therapeutic areas including cardiovascular, metabolic, neurodegenerative and neuropsychiatric disorders. Dr Plowright has led multi-disciplinary teams and organisations in AstraZeneca, Sanofi and Wavebreak Therapeutics prior to PangeaBio. He and his teams have contributed to the delivery of a range of compounds to the clinic, including compounds currently progressing through phase 2 clinical trials. Dr Plowright obtained his PhD at the University of Nottingham, UK and continued with a 2-year postdoctoral study at Harvard University, USA. He has authored more than 75 publications and patents.

Thomas Thum, Prof. Dr.

Professor of Cardiology, Hannover Medical School Founder, CSO/CMO Cardior Pharmaceuticals GmbH

Thomas Thum is a scientist and cardiologist. He is a full professor and director of the Institute of Molecular and Translational Therapeutic Strategies. He (co-) authored more than 500 publications and is a distinguished reviewer, board member, patent holder, and founder.

Prof. Dr. Dr. Thomas Thum
Institute of Molecular and Translational Therapeutic Strategies
Medizinische Hochschule Hannover (MHH) – OE8886
Carl-Neuberg-Str.1, D-30625 Hannover
thum.thomas@mh-hannover.de
https://www.mhh.de/institute-zentren-forschungseinrichtungen/imtts